Antibacterial and anti-atrophic effects of a highly soluble, acid stable UDCA formula in Helicobacter pylori-induced gastritis

被引:17
作者
Thao, Tran Dang Hien [1 ]
Ryu, Ho-Cheol [1 ]
Yoo, Seo-Honq
Rhee, Dong-Kwon [1 ]
机构
[1] Sungkyunkwan Univ, Coll Pharm, Suwon 440746, South Korea
关键词
Helicobacter pylori-induced atrophic gastritis; ursodeoxycholic acid (UDCA); mitochondria; reactive oxygen species;
D O I
10.1016/j.bcp.2008.03.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Helicobacter pylori is one of the main causes of atrophic gastritis and gastric carcinogenesis. Gastritis can also occur in the absence of H. pylori as a result of bile reflux suggesting the eradication of H. pylon by bile acids. However, the bile salts are unable to eradicate H. pylori due to their low solubility and instability at acidic pH. This study examined the effect of a highly soluble and acid stable ursodeoxycholic acid (UDCA) formula on H. pylori-induced atrophic gastritis. The H. pylori infection decreased the body weight, mitochondrial membrane potential and ATP level in vivo. Surprisingly, H. pylori-induced expression of malate dehydrogenase (MDH), a key enzyme in the tricarboxylic acid cycle, at both the protein and mRNA levels. However, the UDCA formula repressed MDH expression and increased the membrane potential thereby increasing the ATP level and body weight in vivo. Moreover, UDCA scavenged the reactive oxygen species (ROS), increased the membrane potential, and inhibited apoptosis in AGS cells exposed to H2O2 in vitro through the mitochondria-mediated pathway. Taken together, UDCA decreases the MDH and ROS levels, which can prevent apoptosis in H. pylori-induced gastritis. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:2135 / 2146
页数:12
相关论文
共 36 条
[1]   THE METABOLIC COST OF FEVER [J].
BARACOS, VE ;
WHITMORE, WT ;
GALE, R .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 1987, 65 (06) :1248-1254
[2]   Ursodeoxycholic acid ameliorates experimental ileitis counteracting intestinal barrier dysfunction and oxidative stress [J].
Bernardes-Silva, CF ;
Damiao, AOMC ;
Sipahi, AM ;
Laurindo, FRM ;
Iriya, K ;
Lopasso, FP ;
Buchpiguel, CA ;
Lordello, MLL ;
Agostinho, CLO ;
Laudanna, AA .
DIGESTIVE DISEASES AND SCIENCES, 2004, 49 (10) :1569-1574
[3]   URSODEOXYCHOLIC ACID FOR TREATMENT OF PRIMARY SCLEROSING CHOLANGITIS - A PLACEBO-CONTROLLED TRIAL [J].
BEUERS, U ;
SPENGLER, U ;
KRUIS, W ;
AYDEMIR, U ;
WIEBECKE, B ;
HELDWEIN, W ;
WEINZIERL, M ;
PAPE, GR ;
SAUERBRUCH, T ;
PAUMGARTNER, G .
HEPATOLOGY, 1992, 16 (03) :707-714
[4]   CHANGES IN CONSTITUTIVE ENZYMES OF CHICK CELLS FOLLOWING INFECTION WITH SEMLIKI FOREST VIRUS [J].
CASSELLS, AC ;
BURKE, DC .
JOURNAL OF GENERAL VIROLOGY, 1973, 18 (FEB) :135-141
[5]   Review article: drug therapy for non-alcoholic fatty liver disease [J].
Comar, KM ;
Sterling, RK .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (02) :207-215
[6]   Ursodeoxycholic acid as adjunctive therapy for problematic type 1 autoimmune hepatitis: A randomized placebo-controlled treatment trial [J].
Czaja, AJ ;
Carpenter, HA ;
Lindor, KD .
HEPATOLOGY, 1999, 30 (06) :1381-1386
[7]  
EARNEST DL, 1994, CANCER RES, V54, P5071
[8]   Reactive oxygen species: A breath of life or death? [J].
Fruehauf, John P. ;
Meyskens, Frank L., Jr. .
CLINICAL CANCER RESEARCH, 2007, 13 (03) :789-794
[9]   Mice deficient in protein tyrosine phosphatase receptor type Z are resistant to gastric ulcer induction by VacA of Helicobacter pylori [J].
Fujikawa, A ;
Shirasaka, D ;
Yamamoto, S ;
Ota, H ;
Yahiro, K ;
Fukada, M ;
Shintani, T ;
Wada, A ;
Aoyama, N ;
Hirayama, T ;
Fukamachi, H ;
Noda, M .
NATURE GENETICS, 2003, 33 (03) :375-381
[10]   Ursodeoxycholate stabilizes phospholipid-rich membranes and mimics the effect of cholesterol: Investigations on large unilamellar vesicles [J].
Guldutuna, S ;
Deisinger, B ;
Weiss, A ;
Freisleben, HJ ;
Zimmer, G ;
Sipos, P ;
Leuschner, U .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1997, 1326 (02) :265-274